Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Abstract Background The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. Methods MEDI0680 was administered intravenously once every 2 weeks (Q...

Full description

Bibliographic Details
Main Authors: Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel, Patricia LoRusso, Amy Weise, Joseph Eder, Brendan Curti, Michael Oberst
Format: Article
Language:English
Published: BMJ Publishing Group 2019-08-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
MEDI0680
PD-1
Immunotherapy
Kidney cancer
Melanoma
Online Access:http://link.springer.com/article/10.1186/s40425-019-0665-2

Internet

http://link.springer.com/article/10.1186/s40425-019-0665-2

Similar Items